Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Non-cash Items (2016 - 2025)

Enanta Pharmaceuticals' Non-cash Items history spans 14 years, with the latest figure at $16.9 million for Q4 2025.

  • For Q4 2025, Non-cash Items changed N/A year-over-year to $16.9 million; the TTM value through Dec 2025 reached $16.9 million, changed N/A, while the annual FY2025 figure was $4.0 million, 16.03% up from the prior year.
  • Non-cash Items reached $16.9 million in Q4 2025 per ENTA's latest filing, up from $6.5 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $97.2 million in Q4 2021 to a low of $2000.0 in Q2 2023.
  • Average Non-cash Items over 5 years is $21.3 million, with a median of $8.4 million recorded in 2023.
  • Peak YoY movement for Non-cash Items: tumbled 99.99% in 2023, then surged 209350.0% in 2024.
  • A 5-year view of Non-cash Items shows it stood at $97.2 million in 2021, then tumbled by 97.24% to $2.7 million in 2022, then increased by 12.77% to $3.0 million in 2023, then plummeted by 53.24% to $1.4 million in 2024, then soared by 1095.83% to $16.9 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Non-cash Items are $16.9 million (Q4 2025), $6.5 million (Q3 2025), and $3.9 million (Q2 2025).